Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_031b407a6c144a91e91831eeb958d415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4319fe3d827bd24add491d4ed90e7692 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-775 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6876 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-616 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
filingDate |
2008-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_468b61b7501ebc37a8d050b704d5ea60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f905093e216bc063fd6897c5b7e97e2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86a5e31465e54863def22d94bd994ea0 |
publicationDate |
2022-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
BR-PI0811309-B1 |
titleOfInvention |
IN VITRO METHODS TO EVALUATE A RESPONSIBILITY OF THE APO(A) GENE IN A NUCLEIC ACID SAMPLE FROM A HUMAN SUBJECT TO ACETYLSALICYLIC ACID TREATMENT TO REDUCE THE RISK OF A FUTURE CARDIOVASCULAR EVENT |
abstract |
POLYMORPHISM IN PREDICTED RECEPTIVITY OF THE APO(A) GENE TO ACETYLSALICYLIC ACID TREATMENT The present invention relates to nucleotide polymorphisms in the Apo(a) genes of humans and the use of Apo(a) nucleotide polymorphisms in the identification of whether a human will or will not respond to treatment with acetylsalicylic acid. |
priorityDate |
2007-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |